Dr. Wang on the Utility of CAR T-Cell Therapy in Relapsed/Refractory MCL

Video

Michael Wang, MD, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma (MCL).

A fraction of MCL is particularly aggressive, says Wang; the disease can progress through multiple lines of chemotherapy and targeted therapies.

CAR T-cell therapy offers an alternate way to treat MCL, explains Wang. T cells are obtained from the patients and are then examined in the lab. A gene transfer is performed, the T cells are put into a product, and then they are put back into the patient. The T cells identify the lymphoma cells, bind to them, and cure them, explains Wang.

Many studies have demonstrated that his approach is very effective, even those done in more aggressive cancers such as acute lymphoblastic leukemia and large cell lymphoma, says Wang.

One such product that is showing promise in this space is KTE-X19. In February 2020, a biologics license application for the agent was granted a priority review designation by the FDA for the treatment of patients with relapsed/refractory MCL based on positive findings from the phase 2 ZUMA-2 trial. Results showed that a single infusion of KTE-X19 elicited a 93% objective response rate and a 67% complete response rate in this patient population.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.